A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice

Liver International

Volumn 31, Issue 4, 2011, Pages 552-560

  Korenaga, Masaaki ^a   Hidaka, Isao ^b   Nishina, Sohji ^a   Sakai, Aya ^b   Shinozaki, Akane ^b   Gondo, Toshikazu ^c   Furutani, Takakazu ^d   Kawano, Hiroo ^b   Sakaida, Isao ^b   Hino, Keisuke ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^d Shuto General Hospital   (Japan)

Author keywords

Carnitine palmitoyl transferase; Mitochondria; Oxidative stress; Reactive oxygen species; Transgenic mice

Indexed keywords

HEPATITIS C VIRUS POLYPROTEIN; IRON; NEOMINOPHAGEN C; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FATTY LIVER; HEPATITIS C VIRUS; IN VIVO STUDY; IRON OVERLOAD; LIPOGENESIS; LIVER PROTECTION; LONG TERM CARE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; CYSTEINE; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FATTY LIVER; GLYCINE; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HEPATITIS C; IMMUNOBLOTTING; IRON; IRON, DIETARY; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; STATISTICS, NONPARAMETRIC; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 79952465186     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02469.x     Document Type: Article

References (31)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Orlent H, Hansen BE, Willems M, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol 2006; 45: 539-46.
4. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-500.
5. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
6. Kitase A, Hino K, Furutani T, et al. In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. J Gastroenterol 2005; 40: 617-24.
7. Barbaro G, Di Lorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999; 94: 2198-205.
8. Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 2087-98.
9. ™, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein. Liver Int 2007; 27: 845-53.
10. Beard MR, Abell G, Honda M, et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology 1999; 30: 316-24.
11. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65.
12. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-7.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
14. Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-38.
15. Harrison-Findik DD, Schafer D, Klein E, et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 2006; 281: 22974-82.
16. Nishina S, Korenaga M, Hino K, et al. Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice. Liver Int 2010; 30: 683-92.
17. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43-55.
18. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 2000; 1486: 1-17.
19. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-8.
20. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
21. Ji C, Kaplowitz N. ER stress: can the liver cope? J Hepatol 2006; 45: 321-33.
22. Calfon M, Zeng H, Urano F, et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002; 415: 92-6.
23. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001; 107: 881-91.
24. Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev 2006; 86: 1133-49.
25. Okada T, Yoshida H, Akazawa R, Negishi M, Mori K. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J 2002; 366: 585-94.
26. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567-71.
27. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
28. Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-702.
29. Hofer H, Osterreicher C, Jessner W, et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004; 40: 1018-22.
30. Rulyak SJ, Eng SC, Patel K, et al. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 2005; 100: 332-7.
31. Schwer B, Ren S, Pietschmann T, et al. Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. J Virol 2004; 78: 7958-68.